Additional trials will explore combining BNT327/PM8002 and BioNTech’s proprietary antibody-drug conjugates (“ADCs”). In June 2024, the evaluation of BNT327/PM8002 in combination with BNT325/DB-1305, a ...
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback